selective, reversible LSD1 inhibitor

<100 mg orally QW, in Ph. II for 1L ES-SCLC

from 300k+ cmpd HTS, SBDD + opt.

J. Med. Chem., Oct. 9, 2020

Celgene/Bristol Myers Squibb, San Diego, CA

Structure of CC-90011

CC-90011 (Celgene/Bristol Myers Squibb (BMS)) selective, reversible LSD1 inhibitor clinical candidate)


get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: